Lipoprotein(a) level and MIF gene variant predict incident metabolic syndrome and mortality

Journal of Investigative Medicine

Volumn 64, Issue 2, 2016, Pages 392-399

  Onat, Altan ^a   Can, Günay ^b   Çoban, Neslihan ^b   Dönmez, Ibrahim ^c   Çakir, Hakan ^d   Ademoǧlu, Evin ^b   Erginel Ünaltuna, Nihan ^b   Yüksel, Hüsniye ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Izzet Baysal University   (Turkey)

^d Darlca Farabi State Hospital   (Turkey)

Author keywords

Autoimmunity; Death; Lipoproteins; Macrophages

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; MIGRATION INHIBITION FACTOR; ISOMERASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MIF PROTEIN, HUMAN;

ADULT; AGE; AGED; ALL CAUSE MORTALITY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; GENE; GENETIC VARIABILITY; GENOTYPE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MIF GENE; MORTALITY RATE; MORTALITY RISK; OUTCOME ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TURK (PEOPLE); BLOOD; GENETICS; MORTALITY; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; FEMALE; HUMANS; INCIDENCE; INTRAMOLECULAR OXIDOREDUCTASES; LIPOPROTEIN(A); MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS;

EID: 84961408703     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.1136/jim-2015-000003     Document Type: Article

References (35)

1. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
2. Nordestgaard BG, Chapman MJ, Ray K, et al., European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53.
3. Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010;55:2160-7.
4. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;381:2518-28.
5. Lanktree MB, Anand SS, Yusuf S, et al. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circulation Cardiov Genet 2010;3:39-46.
6. Onat A, Can G, Örnek E, et al. Abdominal obesity with hypertriglyceridemia, lipoprotein(a) and apolipoprotein A-I, determine marked cardiometabolic risk. Eur J Clin Invest 2013;43:1129-39.
7. Mora S, Kamstrup PR, Rifai N, et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010;56:1252-60.
8. Ye Z, Haycock PC, Gurdasani D, et al The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?. Diabetes 2014;63:332-42.
9. Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014;20:575-84.
10. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966;56:72-7.
11. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003;3:791-800.
12. Calandra T, Bernhagen J, Mitchell RA, et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895-902.
13. Burger-Kentischer A, Goebel H, Seiler R, et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002;105:1561-6.
14. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004;89:5043-7.
15. Skurk T, Herder C, Kraft I, et al. Production and release of macrophage migration inhibitory factorfrom human adipocytes. Endocrinology 2005;146:1006-11.
16. Yabunaka N, Nishihira J, Mizue Y, et al. Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 2000;23:256-8.
17. Herder C, Kolb H, Koenig W, et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 2006;29:368-71.
18. Onat A, Ceyhan K, Başar Ö, et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels. A prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92.
19. Onat A, Can G, Kaya H, et al. "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes and vascular events. J Clin Lipidol 2010;4:89-98.
20. Onat A, Çoban N, Can G, et al. Low "quotient" Lp(a) concentration mediating autoimmune activation predicts cardiometabolic risk. Exp Clin Endocr Diabetes 2015;123:11-18.
21. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1-10.
22. Onat A, Hergenç G, Özhan H, et al. Lipoprotein(a) is associated with coronary heart disease in women independent of metabolic syndrome. Coron Artery Dis 2008;19:125-31.
23. de Kok JB, Wiegerinck ET, Giesendorf BA, et al. Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes). Hum Mutat 2002;19:554-9.
24. Genuth S, Alberti KG, Bennett P, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus: The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:3160-7.
25. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
26. Onat A, Uyarel H, Hergenç G, et al. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007;191:182-90.
27. Kim HR, Lee SA, Kim HJ, et al. Elevated levels of macrophage migration inhibitory factor in women with metabolic syndrome. Hormone Metab Res 2011;43:642-5.
28. Herder C, Klopp N, Baumert J, et al. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetologia 2008;51:276-84.
29. Todros T, Bontempo S, Piccoli E, et al. Increased levels of macrophage migration inhibitory factor (MIF) in preeclampsia. Eur Obst Gynecol Reprod Biol 2005;123:162-6.
30. Cardaropoli S, Ietta F, Romagnoli R, et al. Lower macrophage migration inhibitory factor concentrations in maternal serum before pre-eclampsia onset. J Interferon Cytokine Res 2014;34:537-42.
31. Kraja AT Vaidya D, Pankow JS, et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED Consortium. Diabetes 2011;60:1329-39.
32. Çoban N, Onat A, Yildirim Ö, et al. Oxidative stress-mediated (sex-specific) loss of protection against type-2 diabetes by macrophage migration inhibitory factor (MIF)-173G/C polymorphism. Clin Chim Acta 2015;438:1-6.
33. Onat A, Can G, Ademoǧlu E, et al. Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J Investig Med 2013;61:27-33.
34. Onat A, Yüksel H, Can G, et al. Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders. Scand J Clin Lab Invest 2013;73:569-75.
35. Aggarwal V, Schneider AL, Selvin E. Low hemoglobin A1c in nondiabetic adults: an elevated risk state? Diabetes Care 2012;35:2055-60.